Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations

被引:17
作者
Basavapathruni, Aravind
Vingerhoets, Johan
de Bethune, Marie-Pierre
Chung, Raymond
Bailey, Christopher M.
Kim, Jiae
Anderson, Karen S.
机构
[1] Yale Univ, Dept Pharmacol, Sch Med, New Haven, CT 06520 USA
[2] Tibotec, Clin Virol, Mechelen, Belgium
关键词
D O I
10.1021/bi052362v
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Synergy between the anti-human immunodeficiency virus type 1 (HIV) nucleoside reverse transcriptase (RT) inhibitors (NRTIs) and nonnucleoside RT inhibitors (NNRTIs) results from a general mechanism in which NNRTIs inhibit ATP-mediated removal of NRTIs from chain-terminated primers by decreasing the maximum rate of removal, thus sustaining NRTI chain termination. With this molecular mechanism of synergy, beta-D-(+)-3'-azido-3'-deoxythymidine monophosphate (AZTMP) removal was examined in the context of clinically relevant RT mutants. The IC50 value for inhibition by nevirapine against wild-type (WT) RT in our removal assay was 3 AM, but this concentration had no effect on removal by the nevirapine-resistant Y181C mutant. Rather, a similar to 83-fold increase in nevirapine was required to decrease the rate of removal by 50% for this mutant. Efavirenz displayed a 100 nM IC50 value against WT and the efavirenz-sensitive Y181C mutant, but the efavirenz-resistant mutants K103N and K103N/Y181C required a 6-fold increase in efavirenz concentration to achieve the same effect. A newer generation NNRTI, TMC125, showed potency (55 nM) against WT and all mutants, paralleling the activity of this inhibitor relative to nevirapine and efavirenz in cell culture. When tested against the AZT-resistant mutant, all NNRTIs inhibited removal by greater than 50%, showing that this mutant is hypersensitive to NNRTIs. Altogether these results illustrate that both the NNRTI and NRTI mutations can modulate chain termination. This demonstrates that sustaining synergistic HIV inhibition in combination NRTI/NNRTI therapy requires NNRTIs that are potent against WT virus and possess favorable activity profiles against clinically relevant mutations.
引用
收藏
页码:7334 / 7340
页数:7
相关论文
共 56 条
[1]   TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1 [J].
Andries, K ;
Azijn, H ;
Thielemans, T ;
Ludovici, D ;
Kukla, M ;
Heeres, J ;
Janssen, P ;
De Corte, B ;
Vingerhoets, J ;
Pauwels, R ;
de Béthune, MP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4680-4686
[2]   Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy [J].
Bacheler, L ;
Jeffrey, S ;
Hanna, G ;
D'Aquila, R ;
Wallace, L ;
Logue, K ;
Cordova, B ;
Hertogs, K ;
Larder, B ;
Buckery, R ;
Baker, D ;
Gallagher, K ;
Scarnati, H ;
Tritch, R ;
Rizzo, C .
JOURNAL OF VIROLOGY, 2001, 75 (11) :4999-5008
[3]   Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors [J].
Balzarini, J ;
De Clercq, E ;
Carbonez, A ;
Burt, V ;
Kleim, JP .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (06) :517-528
[4]   Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs [J].
Basavapathruni, A ;
Bailey, CM ;
Anderson, KS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (08) :6221-6224
[5]   The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3′-azido-3′-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1 [J].
Borkow, G ;
Arion, D ;
Wainberg, MA ;
Parniak, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :259-263
[6]   Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of Stavudine and zidovudine and its inhibition by efavirenz [J].
Crespan, E ;
Locatelli, GA ;
Cancio, R ;
Hübscher, U ;
Spadari, S ;
Maga, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (01) :342-349
[7]   Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3'-azido-3'-deoxythymidine with nonnucleoside lnhibitors [J].
Cruchaga, C ;
Odriozola, L ;
Andréola, M ;
Tarrago-Litvak, L ;
Martínez-Irujo, JJ .
BIOCHEMISTRY, 2005, 44 (09) :3535-3546
[8]   Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants [J].
Das, K ;
Clark, AD ;
Lewi, PJ ;
Heeres, J ;
de Jonge, MR ;
Koymans, LMH ;
Vinkers, HM ;
Daeyaert, F ;
Ludovici, DW ;
Kukla, MJ ;
De Corte, B ;
Kavash, RW ;
Ho, CY ;
Ye, H ;
Lichtenstein, MA ;
Andries, K ;
Pauwels, R ;
de Béthune, MP ;
Boyer, PL ;
Clark, P ;
Hughes, SH ;
Janssen, PAJ ;
Arnold, E .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (10) :2550-2560
[9]   Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Past, present, and future [J].
De Clercq, E .
CHEMISTRY & BIODIVERSITY, 2004, 1 (01) :44-64
[10]   The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection [J].
De Clercq, E .
ANTIVIRAL RESEARCH, 1998, 38 (03) :153-179